Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VMD-928 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- VM Oncology, LLC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
VMD-928 + pembrolizumab is an investigational combination therapy being developed by VM Oncology, LLC for the treatment of TrkA-driven advanced solid tumors and lymphoma. VMD-928 is a first-in-class, oral, selective, allosteric, and irreversible inhibitor of Tropomyosin receptor kinase A (TrkA/NTRK1). Unlike traditional ATP-competitive inhibitors, VMD-928 binds to an allosteric site, which may provide superior selectivity and overcome resistance mechanisms associated with ATP-binding site mutations. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as a checkpoint inhibitor to restore T-cell mediated anti-tumor immunity. This combination aims to synergistically inhibit tumor growth and enhance the immune response in patients with tumors overexpressing TrkA protein.
- Other names
- VMD-928 + pembrolizumab
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on VMD-928 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VMD-928 + pembrolizumab.